Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate | Zendy

Emiel A. De Jaeghere | Zendy; Félix Gremonprez | Zendy; Philippe Tummers | Zendy; Wouter C. Willaert | Zendy; Wim Ceelen | Zendy; Frédéric Amant | Zendy; Hannelore Denys | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate

Author(s) -

Emiel A. De Jaeghere,

Félix Gremonprez,

Philippe Tummers,

Wouter C. Willaert,

Wim Ceelen,

Frédéric Amant,

Hannelore Denys

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.01179

Subject(s) - medicine , ovarian cancer , intraperitoneal chemotherapy , platinum , oncology , cancer , biochemistry , chemistry , catalysis

In their recent article in Journal of Clinical Oncology, Walker et al reported the efficacy and toxicity profile of bevacizumab with intravenous (IV) versus intraperitoneal (IP) chemotherapy for newly diagnosed advanced ovarian cancer in a large intergroup phase III trial (Gynecologic Oncology Group [GOG] 252 trial). Although we appreciate their findings, we believe that the interpretation of the results raises a few important issues for the authors to clarify.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research